Business
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
- IMM-BCP-01 is a cocktail of three antibodies that target unique regions of the spike protein, including highly conserved epitopes. -The cocktail exhibits
About this update from Immunome, Inc.
[{"type":"text","content":"\n- IMM-BCP-01 is a cocktail of three antibodies that target unique regions of the spike protein, including highly conserved epitopes.\n\n -The cocktail exhibits potent anti-viral activity against multiple SARS-CoV-2 isolates, including current and former CDC variants of concern, Delta, Alpha, Beta, and Gamma\n\n EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication.\n\nIMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes. In preclinical testing, the antibodies exhibit combinatorial effects against multiple SARS-CoV-2 strains, including CDC variants of concern, and significantly reduces viral load in the lungs of hamsters infected with a SARS-CoV-2 reference strain.\n\nImmunome’s preclinical research demonstrates:\n\n\nThe three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner.\n\n\nThe first antibody binds to a sub-dominant epitope of the spike protein, which appears to be broadly conserved across all current and former SARS-CoV-2 variants of concern as well as other Betacoronaviruses and SARS-COV-1.\n\n\nThe second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism.\n\n\nThe third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop.\n\n\n\n\nAs a cocktail, the three antibodies demonstrate enhanced anti-viral activity.\n\n\nEfficacious in pseudovirus neutralization against the CDC variant of concern, Delta.\n\n\nShows equal or better activity against live virus in the reference and the variants tested to-date (Alpha, Beta and Gamma).\n\n\nPotent activation of phagocytosis and complement fixation – known to be critical for in vivo treatment efficacy\n\n\n\n\nIn both treatment and prophylactic settings, at corresponding doses of up to 9 mg/kg, the cocktail potently reduced ...